Medical devices, healthcare technology and the business of care
PMA approval · P100046

ATRICURE SYNERGY ABLATION SYSTEM

AtriCure, Inc. · Decision date Dec 14, 2011

FDA DECISIONP100046

What did the FDA approve?

FDA records P100046 as an original PMA application. The recorded decision is approval, dated Dec 14, 2011.

FDA approval order statement

APPROVAL FOR THE ATRICURE SYNERGY ABLATION SYSTEM. THIS DEVICE IS INDICATED FOR THE ABLATION OF CARDIAC TISSUE FOR THETREATMENT OF PERSISTENT ATRIAL FIBRILLATION (SUSTAINED BEYOND SEVEN DAYS, OR LASTING LESS THAN SEVEN DAYS BUT NECESSITATING PHARMACOLOGIC OR ELECTRICAL CARDIOVERSION) OR LONGSTANDING PERSISTENT ATRIALFIBRILLATION (CONTINUOUS ATRIAL FIBRILLATION OF GREATER THAN ONE YEAR DURATION) IN PATIENTS WHO ARE UNDERGOING OPEN CONCOMITANT CORONARY ARTERY BYPASS GRAFTING AND/OR VALVE REPLACEMENT OR REPAIR.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Dec 14, 2011

FDA source record

Regulatory record facts

Identifier
P100046
Regulatory pathway
Premarket approval application
Product code
OCM
Decision code
APPR
Decision date
Dec 14, 2011
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Surgical cardiac ablation device, for treatment of atrial fibrillation.

Product code
OCM
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P100046 received

    Application receipt date recorded by FDA.

  2. P100046 · FDA decision

    APPR

  3. P100046/S021 · Related supplement

    Synergy Ablation System

Timeline entries are records held by MedtechLedger for P100046. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100046

Product / regulatory recordCompanyPathwayDecision dateSource
AtriCure, Inc.PMA supplementSep 24, 2026FDA

Explore the linked device profile

Other records with product code OCM

Product / regulatory recordCompanyPathwayDecision dateSource
AtriCure, Inc.PMA supplementSep 24, 2026FDA
AtriCure, Inc.PMA approvalApr 28, 2021FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

AtriCure, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
7555 Innovation Way, Mason, OH, 45040

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records